PharmaBlock Sciences Nanjing Inc
SZSE:300725

Watchlist Manager
PharmaBlock Sciences Nanjing Inc Logo
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Watchlist
Price: 35.24 CNY 2.23% Market Closed
Market Cap: 7B CNY
Have any thoughts about
PharmaBlock Sciences Nanjing Inc?
Write Note

PharmaBlock Sciences Nanjing Inc
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

PharmaBlock Sciences Nanjing Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Net Change in Cash
-ÂĄ741.7m
CAGR 3-Years
N/A
CAGR 5-Years
-128%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Change in Cash
ÂĄ3.3B
CAGR 3-Years
N/A
CAGR 5-Years
37%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Change in Cash
ÂĄ6.1B
CAGR 3-Years
131%
CAGR 5-Years
26%
CAGR 10-Years
45%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Change in Cash
ÂĄ4.4B
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Change in Cash
ÂĄ1.6B
CAGR 3-Years
-25%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Change in Cash
-ÂĄ609m
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PharmaBlock Sciences Nanjing Inc
Glance View

Market Cap
7B CNY
Industry
Pharmaceuticals

PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.

Intrinsic Value
53.37 CNY
Undervaluation 34%
Intrinsic Value
Price

See Also

What is PharmaBlock Sciences Nanjing Inc's Net Change in Cash?
Net Change in Cash
-741.7m CNY

Based on the financial report for Sep 30, 2024, PharmaBlock Sciences Nanjing Inc's Net Change in Cash amounts to -741.7m CNY.

What is PharmaBlock Sciences Nanjing Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
-128%

Back to Top